XOMA posts GAAP profit as royalty portfolio grows; debt and counterparty risks loom

XOMA Royalty Corporation (NASDAQ: XOMA) - Quick take

What's happening inside: XOMA is executing its royalty-aggregator strategy - buying royalty/milestone streams and making targeted acquisitions (BioInvent, Castle Creek, Pulmokine) while monetizing select Kinnate assets. The company is generating cash from commercial receipts (notably VABYSMO and OJEMDA) and recognizing gains on equity holdings, but it carries meaningful long-term debt and an accumulated deficit.

Key facts & statistics (straight to the point)

* Cash and equivalents: $75,060k; total cash, cash equivalents and restricted cash: $78,485k (June 30, 2025).
* Total assets: $223,456k; Total liabilities: $131,002k; Stockholders' equity: $72,435k (June 30, 2025).
* Net income (Q2 2025): $9,191k; Net income (six months 2025): $11,558k. Basic EPS Q2: $0.46; Diluted EPS Q2: $0.44.
* Total income & revenues (Q2 2025): $13,129k (up from $11,086k in Q2 2024). Six months: $29,041k vs $12,576k prior year.
* Income from purchased receivables (EIR): $6,007k (Q2); cost-recovery method: $1,743k (Q2).
* Revenue from contracts (milestones/license): $5,025k (Q2) - includes $5.0M Rezolute milestone in Q2.
* General & administrative expense (Q2 2025): $7,802k (down from $11,004k Q2 2024).
* R&D expense (Q2 2025): $69k (sharp reduction vs $1,161k prior-year quarter).
* Interest expense (Q2 2025): $3,236k (related to Blue Owl loan).
* Long-term debt (Blue Owl initial term loan carrying value): $102,201k (long-term portion). Gross principal originally $130,000k.
* Intangible assets (net): $45,434k (Pulmokine seralutinib $24,821k; BioInvent contract-based asset $20,613k).
* Royalty & commercial payment receivables under cost-recovery (long-term): $58,937k; under EIR (total): $22,735k (June 30, 2025).
* Convertible preferred stock recorded as mezzanine/temporary equity: $20,019k.
* Equity securities fair-value gains: $6,320k (Q2 2025) contributed to other income; other income, net Q2: $7,824k.

Positive aspects of the income statement

* Returned to GAAP net income in the quarter: Q2 2025 net income $9.2M after prior operating losses.
* Revenue diversification: combination of EIR income (VABYSMO), cost-recovery receipts (OJEMDA), and milestone/license revenues (Rezolute, Takeda) - total income and revenues up materially year-over-year for six months.
* Improved operating cash flow: net cash from operations $8,668k for the six months ended June 30, 2025 (turnaround vs prior periods).
* G&A and R&D expense reductions vs prior-year quarter - lower cash burn on operating lines.

Negative / risk aspects of the income statement

* Heavy reliance on partner payments and milestones - significant revenue concentration: in Q2 three partners accounted for 44%, 38% and 13% of total income and revenues.
* Large interest burden: $3.2M interest expense in Q2 (high fixed rate tied to Blue Owl loan) and significant long-term debt outstanding (~$102.2M).
* Many acquired assets still on cost-recovery accounting (no earnings recognized until cost recovered) - long runway before some assets produce accretable income (Daré, Twist, Palo, Kuros, etc.). Long-term receivables under cost recovery: $58.9M.
* Accumulated deficit remains large: $(1,227,892)k - company still structurally lossful over time despite recent profitable quarter.
* Concentration of receivables: one partner represented 94% of trade & other receivables as of June 30, 2025 - counterparty concentration risk.
* Potential contingent liabilities: Exarafenib contingent consideration $3,402k (Level 3 fair-value liability) and contingent payments (e.g., $10M BioInvent contingent payment) that could become cash outflows upon milestones.
* Cash declined vs Dec 31, 2024: unrestricted cash from $101.654M to $75.060M - driven by acquisitions (BioInvent $20.6M) and other investing outflows.

Bottom line: XOMA is actively growing its royalty portfolio and showing improving operating results and cash from operations in 1H‑2025. However, the business is still capital-intensive and dependent on partner performance and milestone timing, with concentrated counterparties and a sizable secured loan (high interest) on the balance sheet. Watch cash/debt dynamics, milestone outcomes for cost-recovery assets, and concentration of receipts when evaluating risk/reward.

If you want, I can: (a) pull the most material drivers for forward revenue (VABYSMO, OJEMDA, Rezolute timing), (b) map expected maturities/interest schedule on the Blue Owl loan, or (c) prepare a one‑page risk checklist for investors.